VivoSeq
Cardiovascular

Acute Myocardial Infarction (AMI)

2

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Acute Myocardial Infarction (AMI) is an early-stage landscape with 2 programs across 1 company. The most active players are Idoven 1903 S.L.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Idoven 1903 S.L.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Zastaprazan

Yonsei University

Proton Pump Inhibitors

Samsung Medical Center

Approved
No programs

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Active, not recruiting1 · 20%
Not yet recruiting1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
Completed·BBrigham and Women's Hospital·N/A·NCT07610577·377,753 enrolled
Improved Management of Acute Chest Pain in Emergency Primary Care. The OUT-POC Study (One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care)
Active, not recruiting·UUniversity of Oslo·Preclinical·NCT06853626·2,500 enrolled
Early Ga-68 FAPI PET/MR for Assessment of Left Ventricular Remodeling After Acute Myocardial Infarction: A Prospective Single-Center Observational Study
Not yet recruiting·AAnkara University·N/A·NCT07684924·25 enrolled
Artificial Intelligence Scalable Solution for ST Myocardial Infarction (ASSIST): Cross-sectional Study
Completed·IIdoven 1903 S.L.·N/A·NCT06939738·489 enrolled
Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial
Recruiting·SSamsung Medical Center·Phase 3·NCT07467213·5,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)